Metabolomic Diagnostics, has secured an additional €1.6 million in from investors to help complete PrePsia™, its new screening test for pre-eclampsia in first time pregnant mothers. This latest funding round is supported by existing investors, SOSventures, Enterprise Equity and Enterprise Ireland as well as a number [...]
Metabolomic Diagnostics have expanded its team by recruiting Paloma Muñiz Ortea and Leslie Brown. Ms. Muñiz Ortea is our R&D Product Development manager. Paloma is trained as an analytical chemist and holds a PhD from the Cork Institute of Technology where she developed analytical methods [...]
As a nationally recognized health observance, Preeclampsia Awareness Month presents the perfect opportunity for the Preeclampsia Foundation to offer education and events that will increase awareness of this life-threatening hypertensive disorder of pregnancy, which occurs in up to eight percent of all pregnancies. The Preeclampsia [...]
Metabolomic Diagnostics’ Director of R&D, Dr. Robin Tuytten will attend the SRI’s 63rd Annual Scientific Meeting, which will take place at the Palais des congres de Montreal in Montreal, QC, Canada, from March 16 – 19, 2016. Prof. Louise Kenny of the Irish Centre for Fetal [...]
Yesterday afternoon, Metabolomic Diagnostics’ Director of R&D, Dr. Robin Tuytten, hosted a complimentary webinar on Stratification for Pre-eclampsia: Lessons Learned from Translation of a Metabolomics Discovery to a Robust LC-MS-20160229 1400-1. The event was hosted by the AACC and sponsored by Agilent Technologies. If you missed [...]
On February 29th, join Metabolomic Diagnostics’ Director of R&D, Dr. Robin Tuytten, for an informative look at what it takes to translate the results of an unbiased metabolomics discovery study into a robust analytical pipeline centered around a research-use-only, semi-quantitative LC-MS/MS methodology. Registration is complimentary. [...]